--- title: 'VP, Global Rare Disease Franchise at REGENXBIO' canonical: 'https://feeny.ai/job/vp-global-rare-disease-franchise-regenxbio-remote-zw2996mdrwy4' type: 'job' last_seen: '2026-11-02' --- # VP, Global Rare Disease Franchise at REGENXBIO - **Company:** REGENXBIO - **Location:** Remote - **Employment:** full-time - **Work type:** remote - **Posted:** 2026-10-01 - **Last confirmed live:** 2026-11-02 - **Apply:** https://jobs.lever.co/regenxbio/31d38d4f-58f7-4af4-9269-c3aa92795b5a ## Job description Since our founding in 2009, REGENXBIO has pioneered what’s possible in gene therapy. Today, we are advancing a pipeline of gene therapies designed to improve the lives of patients facing serious rare and retinal diseases and preparing to bring innovative new medicines to patients. Our work is fueled by purpose and urgency because every day matters to patients and their families. At REGENXBIO, you’ll find meaningful opportunities to grow, collaborate, and contribute to the advancement of potentially transformative gene therapies. Together, our talented team is working to make a meaningful difference for patients and their families. What we do matters. The opportunity As VP, Global Rare Disease Franchise, you’ll lead the overall strategy and commercialization of REGENXBIO’s rare disease portfolio. With full accountability for business performance and P&L, you’ll lead the commercial strategy and launch of RGX-202 while shaping the growth and evolution of our rare disease franchise.  Reporting to the Chief Commercial Officer, you'll lead the Rare Disease Franchise and Marketing organization, partnering cross-functionally to turn strategy into execution and deliver meaningful outcomes for patients, providers, and the company. As a member of the commercial leadership team, you’ll also help shape REGENXBIO’s global growth strategy and strengthen our leadership in rare disease. ## What you’ll be doing - Own the overall rare disease franchise strategy, business performance, and P&L, with full accountability for revenue, profitability, forecasting, budget, resource allocation, and achievement of commercial objectives, including: - Lead the development and execution of the overall rare disease franchise strategy and commercialization roadmap for RGX-202, and all future programs and products - Establish clear business objectives, performance metrics, and operating plans to maximize franchise growth and long-term value - Own the annual operating plan, revenue forecast, expense budget, and resource allocation for the rare disease franchise, ensuring disciplined investment and accountability for financial performance - Regularly assess market, competitive, customer, and business performance and adjust franchise strategy and investments to maximize growth and P&L performance - Partner closely with Finance and executive leadership to ensure financial rigor, transparency, and accountability across the franchise - Lead the commercial strategy for rare disease product launches, including: - Develop and oversee the integrated U.S. launch strategy, roadmap, and market entry plan for RGX-202 in partnership with key functional leaders. - Establish launch objectives, readiness milestones, performance measures, and operating plans, ensuring organizational alignment and accountability for execution. - Identify and address critical launch barriers across market development, patient identification and referral, treatment-center readiness, access and reimbursement, and patient onboarding, in partnership with functional leaders. - Manage the REGENXBIO rare disease franchise’s performance and growth, with full P&L responsibility, including accountability for: - Revenue and demand generation - Commercial operating expenses and resource allocation - Annual business planning, forecasting, and performance management - Investment decisions and prioritization of resources across the franchise - Identifying and addressing risks and opportunities that impact financial and business performance - Delivering sustainable growth and maximizing the long-term value of the rare disease franchise - Partner with the REGENXBIO executive and senior leadership team to align on strategy and plans for global commercialization, including: - Translate enterprise strategy into clear franchise priorities, operating plans, and measurable business outcomes - Provide senior leadership with a clear view of market dynamics, business performance, risks, opportunities, and resource requirements - Drive cross-functional alignment and accountability for critical commercial and franchise initiatives - Serve as a senior member of the commercial and management teams of REGENXBIO and contribute to its overall growth strategy, including: - Bring an enterprise perspective to strategic decisions regarding commercialization, portfolio prioritization, business development, and resource allocation - Represent the voice of the rare disease community within broader company strategy and decision-making - Partner with executive leadership to identify opportunities to strengthen the company’s commercial capabilities and long-term growth - Collaborate with partners in R&D to be responsible for the rare neuromuscular and muscle Franchise and lead the cross-functional Leadership and Strategy Plans for this therapeutic area for REGENXBIO, including: - Align commercial, clinical, medical, regulatory, market access, and operational priorities across the franchise - Inform pipeline strategy and development priorities based on evolving market, customer, patient, and competitive insights - Ensure appropriate commercial and market development input into development plans and lifecycle strategies - Elevate the company’s external leadership in Rare diseases through industry thought leadership; symposia and key associations. - Ability to travel as required. - It is imperative that REGENXBIO employees embody our core values by working collaboratively, building strong relationships and using clear communication to meet shared objectives. ## What we’re looking for We set our employees up for success.  To be successful in this role and help us achieve our goals, we are looking for someone with the following skills and qualifications: - Advanced degree in relevant life sciences or finance (Ph.D., MBA, MS) is required - 15+ years progressive commercial leadership experience in biotechnology or pharmaceuticals, including leadership of substantial commercial teams and/or businesses. - Demonstrated experience successfully leading a product launch and/or holding significant leadership accountability for launch strategy, readiness, and execution. - Demonstrated ability to translate commercial and franchise strategy into clear business priorities and performance expectations, and partner with field and functional leaders to drive execution. - Strong business and financial acumen, including meaningful responsibility for revenue, operating budgets, forecasting, resource allocation, and investment decisions. - Demonstrated experience operating effectively in highly cross-functional environments and influencing senior leaders across Commercial, Medical, R&D, Market Access, Finance, and other functions. - Demonstrated ability to build organizations and capabilities, develop high-performing teams, and lead effectively through ambiguity and change. Preferred experience includes: - Significant rare disease commercial leadership experience. - Experience commercializing therapies with complex patient journeys, concentrated treatment-center models, and significant institutional access and reimbursement requirements. - Experience with gene therapy, one-time therapies, biologics, and/or other highly complex specialty treatment models. - Experience contributing to lifecycle, pipeline, portfolio, or business-development decisions from a commercial perspective. Why should you apply? By joining REGENXBIO, you will have the opportunity to be a part of a growing company, with an incredible team, who is passionate about developing novel AAV gene therapies for patients in need. We offer a comprehensive and competitive benefit & compensation package which includes market-competitive salaries, an annual bonus program, education assistance, retirement plan with employer match, stock options at all levels, summer hours and more! The estimated compensation range for this role is $289,000 to $410,000 annually. The actual salary offered to the final candidate depends on a number of factors such as relevant work experience, skills, education, and years of experience. In addition, professional development is important to us.  By joining our team, you’ll have the opportunity to be exposed to challenging projects and have access to development resources to help you grow personally and professionally. ## About REGENXBIO ## Company Overview - **One-liner**: REGENXBIO is a clinical-stage biotechnology company developing one-time gene therapies for rare and retinal diseases using its proprietary AAV vector platform. - **Entity Type**: Public (NASDAQ: RGNX) - **Headquarters**: Rockville, Maryland, United States - **Founded**: 2008 (founded as a company; operations began in 2009) - **Founders**: Not publicly listed as individual founders; the company was spun out from the gene therapy research of the University of Pennsylvania and licensed its NAV Technology Platform from the university. ## Core Business - **Primary industry**: Biotechnology – Gene Therapy (AAV-based) - **Target customers**: B2B (pharma partners like AbbVie, Nippon Shinyaku) and B2G (regulatory agencies, clinical trial sites); ultimate customers are patients with rare and retinal diseases (Duchenne muscular dystrophy, MPS I, MPS II, wet AMD, diabetic retinopathy). - **Mission or purpose statement**: “To improve lives through the curative potential of gene therapy.” [regenxbio.com](https://www.regenxbio.com/culture-careers/) ## Products & Services - **NAV® Technology Platform**: Proprietary AAV vector gene delivery platform (including AAV8 and AAV9) used for internal programs and licensed to partners (e.g., Novartis for ZOLGENSMA®). - **ABBV-RGX-314** (in collaboration with AbbVie): Investigational one-time gene therapy for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR). In pivotal clinical trials. - **RGX-202** (Duchenne muscular dystrophy): Phase I/II/III AFFINITY DUCHENNE® trial; pivotal phase expected to support BLA submission in 2026 using accelerated approval pathway. [ir.regenxbio.com](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa) - **RGX-121** (MPS II – Hunter syndrome): In partnership with Nippon Shinyaku; late-stage development. - **RGX-111** (MPS I – Hurler syndrome): In partnership with Nippon Shinyaku; clinical development. - **Manufacturing**: In-house cGMP production facility (REGENXBIO Manufacturing Innovation Center – RMIC) in Rockville, MD, operational since mid-2022. ## Market Standing - **Valuation/Market Cap**: $447.8 million (as of recent data). [linkedin.com](https://linkedin.com/company/regenx) - **Key Metric**: Annual Revenue $170.4 million (primarily from license and collaboration revenue). [linkedin.com](https://linkedin.com/company/regenx) - **Notable Investors/Partners**: - AbbVie (collaboration for ABBV-RGX-314) - Nippon Shinyaku (partnerships for RGX-121 and RGX-111) - Novartis (licensee for ZOLGENSMA® using NAV vectors) - **Growth Signals**: - Headcount: 296 employees (+1.3% YoY). [linkedin.com](https://linkedin.com/company/regenx) - BLA submission for RGX-202 targeted for 2026. - RMIC facility operational since 2022, enabling scalable clinical and commercial manufacturing. - Scholarly output: 160 works, 7,337 citations, field-weighted citation impact of 2.6 (highly influential). [linkedin.com](https://linkedin.com/company/regenx) ## Competitive Advantages - **Proprietary NAV Technology Platform**: Exclusive rights to a large portfolio of AAV vectors (including AAV8 and AAV9), the foundation for multiple approved and investigational gene therapies. [ir.regenxbio.com](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa) - **End-to-end capabilities**: Integrated in-house R&D, preclinical development, clinical development, and cGMP manufacturing. - **Proven platform**: Thousands of patients have been treated with AAV vectors from the NAV platform (including via Novartis’ ZOLGENSMA®). - **Late-stage pipeline**: Multiple programs in pivotal or near-pivotal trials (RGX-202, ABBV-RGX-314) with clear regulatory pathways. ## Strategic Focus - **Near-term**: Advance RGX-202 toward BLA submission in 2026; continue pivotal trials for ABBV-RGX-314 in wet AMD and diabetic retinopathy. - **Long-term**: Expand pipeline in retinal, neuromuscular, and neurodegenerative diseases; leverage RMIC for commercial-scale manufacturing; deepen partnerships with AbbVie and Nippon Shinyaku. - **Platform expansion**: Ongoing research to expand NAV vector capabilities and develop new AAV-based therapies. ## Why Work Here - **Mission-driven culture**: “Patient-focused, driven by results, fosters collaboration.” Core values emphasize accountability, innovation, and serving patients with limited therapeutic options. [regenxbio.com](https://www.regenxbio.com/culture-careers/) - **Impactful work**: Opportunity to work on one-time gene therapies that could fundamentally alter the course of devastating diseases. - **Growth & stability**: Public company with late-stage pipeline, strong partnerships, and a clear path to commercialization. - **Location & facilities**: Headquarters in Rockville, MD, with a state-of-the-art cGMP manufacturing facility (RMIC) on site. - **Work policy**: Not explicitly stated as remote/hybrid; positions appear to be on-site (based on job listings in Rockville and field-based Medical Science Liaison roles). - **Perks**: Comprehensive and competitive benefits for employees and families. [regenxbio.com](https://www.regenxbio.com/culture-careers/) - **Engineering & science culture**: High scholarly output and citation impact; emphasis on cross-functional collaboration between research, manufacturing, and clinical teams. - **Recruitment note**: REGENXBIO warns of fraudulent job offers; all applications go through their official Lever portal. [regenxbio.com](https://www.regenxbio.com/culture-careers/) ## Sources 1. [regenxbio.com – Culture & Careers](https://www.regenxbio.com/culture-careers/) 2. [linkedin.com – REGENXBIO company page](https://linkedin.com/company/regenx) 3. [ir.regenxbio.com – 10-K Filing (Business Overview)](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa) 4. [ir.regenxbio.com – Investor Overview](https://ir.regenxbio.com/investor-overview) 5. [jobs.lever.co – REGENXBIO careers](https://jobs.lever.co/regenxbio) ## Other roles at REGENXBIO - [Lead Integration Developer](https://feeny.ai/job/lead-integration-developer-regenxbio-rockville-x52a6y2n5b0w) — Rockville, MD - [Vice President, Information Technology](https://feeny.ai/job/vice-president-information-technology-regenxbio-rockville-ekqdx4dtve6s) — Rockville, MD - [People Intern](https://feeny.ai/job/people-intern-regenxbio-rockville-mq2tm3vcjxe7) — Rockville, MD - [Associate Director, Regulatory Affairs](https://feeny.ai/job/associate-director-regulatory-affairs-regenxbio-rockville-1grfyr3vz4sy) — Rockville, MD - [Head of Sales, Rare Disease](https://feeny.ai/job/head-of-sales-rare-disease-regenxbio-remote-qhp7fgpvfvzm) - [Associate Director, People Business Partner](https://feeny.ai/job/associate-director-people-business-partner-regenxbio-rockville-fmx3gbzx681y) — Rockville, MD - [Director, Commercial Data, Advanced Analytics & Forecasting](https://feeny.ai/job/director-commercial-data-advanced-analytics-forecasting-regenxbio-remote-88y6fvc5kv5j) - [Associate Director, Rare Disease Product Marketing](https://feeny.ai/job/associate-director-rare-disease-product-marketing-regenxbio-rockville-r2p05phcvmx8) — Rockville, MD - [Senior Director, Global Program Development Lead - DMD/Neuromuscular](https://feeny.ai/job/senior-director-global-program-development-lead-dmd-neuromuscular-regenxbio-xbereeg0zrc8) — Rockville, MD - [Senior Director/Director, Medical Science Liaisons (Neuromuscular/DMD)](https://feeny.ai/job/senior-director-director-medical-science-liaisons-neuromuscular-dmd-regenxbio-aeca83gb75e2)